TherapeuticsMD, Inc. — Director's Dealing 2016

Mar 14, 2016

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: TherapeuticsMD, Inc. (TXMD)
CIK: 0000025743
Period of Report: 2016-03-10

Reporting Person: Collins Cooper C. (Director)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2016-03-11	Common Stock	P	16000	$6.2323	Acquired	36000	Direct

Footnotes

F1: These shares were purchased in multiple transactions at prices ranging from $6.18 to $6.29, inclusive; the price reported reflects the weighted average price. The reporting person undertakes to provide to TherapeuticsMD, Inc. (the "Company"), any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.